{
    "id": 3969,
    "name": "thyroid gland papillary carcinoma",
    "source": "DOID",
    "definition": "A differentiated thyroid gland carcinoma that is characterized by the small mushroom shape of the tumor which has a stem attached to the epithelial layer abd arises from the follicular cells of the thyroid gland. [url:http\\://cancergenome.nih.gov/cancersselected/thyroid, url:http\\://en.wikipedia.org/wiki/Papillary_thyroid_cancer, url:https\\://www.ncbi.nlm.nih.gov/pubmed/21455196]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:3969",
    "evidence": [
        {
            "id": 887,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Cyramza (ramucirumab) demonstrated safety and efficacy resulting in partial response or stable disease in patients with advanced solid tumors, including papillary thyroid carcinoma (PMID: 20048182).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 886,
                "therapyName": "Ramucirumab",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 577,
                    "pubMedId": 20048182,
                    "title": "Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20048182"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1768,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and activation of downstream signaling, and decreased growth of papillary thyroid carcinoma cells harboring the RET/PTC1 oncogene in culture (PMID: 17664273).",
            "molecularProfile": {
                "id": 1326,
                "profileName": "RET rearrange"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 589,
                    "pubMedId": 17664273,
                    "title": "Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17664273"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1778,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) decreased proliferation of papillary thyroid carcinoma cells harboring the RET/PTC1 rearrangement in culture (PMID: 23526464).",
            "molecularProfile": {
                "id": 1326,
                "profileName": "RET rearrange"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 312,
                    "pubMedId": 23526464,
                    "title": "Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23526464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3679,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometiq (cabozantinib) inhibited RET phosphorylation and proliferation of papillary thyroid carcinoma cells harboring CCDC6-RET in culture (PMID: 21470995).",
            "molecularProfile": {
                "id": 10079,
                "profileName": "CCDC6 - RET"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3987,
                    "pubMedId": 21470995,
                    "title": "The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21470995"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5161,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XMD15-44 inhibited RET phosphorylation and downstream signaling and reduced proliferation of papillary thyroid carcinoma cells harboring CCDC6-RET in culture (PMID: 26046350).",
            "molecularProfile": {
                "id": 10079,
                "profileName": "CCDC6 - RET"
            },
            "therapy": {
                "id": 3761,
                "therapyName": "XMD15-44",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4887,
                    "pubMedId": 26046350,
                    "title": "Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26046350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5162,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling, reduced proliferation of papillary thyroid carcinoma cells harboring CCDC6-RET in culture (PMID: 26046350).",
            "molecularProfile": {
                "id": 10079,
                "profileName": "CCDC6 - RET"
            },
            "therapy": {
                "id": 3274,
                "therapyName": "ALW-II-41-27",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4887,
                    "pubMedId": 26046350,
                    "title": "Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26046350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5163,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, HG-6-63-01 inhibited RET phosphorylation and downstream signaling and reduced proliferation of papillary thyroid carcinoma cells harboring CCDC6-RET in culture (PMID: 26046350).",
            "molecularProfile": {
                "id": 10079,
                "profileName": "CCDC6 - RET"
            },
            "therapy": {
                "id": 3762,
                "therapyName": "HG-6-63-01",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4887,
                    "pubMedId": 26046350,
                    "title": "Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26046350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7069,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Caprelsa (vandetanib) and Afinitor (everolimus) combination treatment resulted in enhanced growth inhibition compared to single agent treatment in papillary thyroid cancer cells over-expressing CCDC6-RET in culture (J Clin Oncol 34, 2016 (suppl; abstr 9069)).",
            "molecularProfile": {
                "id": 10079,
                "profileName": "CCDC6 - RET"
            },
            "therapy": {
                "id": 1163,
                "therapyName": "Everolimus + Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6065,
                    "pubMedId": null,
                    "title": "Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion.",
                    "url": "http://meetinglibrary.asco.org/content/170878-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8076,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD1480 reduced phosphorylation of RET and downstream effectors, and induced cell cycle arrest and inhibited growth of a papillary thyroid cancer cell line harboring CCDC6-RET (RET/PTC1) in culture, and induced tumor regression in a cell line xenograft model of CCDC6-RET-positive papillary thyroid cancer (PMID: 23056499).",
            "molecularProfile": {
                "id": 10079,
                "profileName": "CCDC6 - RET"
            },
            "therapy": {
                "id": 652,
                "therapyName": "AZD1480",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6545,
                    "pubMedId": 23056499,
                    "title": "AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23056499"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8216,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with PI3K/AKT pathway alterations in culture, including a papillary thyroid cancer cell line harboring PIK3CA E542K (PMID: 21289267).",
            "molecularProfile": {
                "id": 808,
                "profileName": "PIK3CA E542K"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6573,
                    "pubMedId": 21289267,
                    "title": "The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21289267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8219,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with PI3K/AKT pathway alterations in culture, including a papillary thyroid cancer cell line harboring CCDC6-RET (RET/PTC1) (PMID: 21289267).",
            "molecularProfile": {
                "id": 10079,
                "profileName": "CCDC6 - RET"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6573,
                    "pubMedId": 21289267,
                    "title": "The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21289267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8223,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MK2206 suppressed activation of AKT induced by Torisel (temsirolimus), and MK2206 and Torisel (temsirolimus) demonstrated synergy in inhibiting growth of a papillary thyroid cancer cell line harboring PIK3CA E542K in culture (PMID: 21289267).",
            "molecularProfile": {
                "id": 808,
                "profileName": "PIK3CA E542K"
            },
            "therapy": {
                "id": 4664,
                "therapyName": "MK2206 + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6573,
                    "pubMedId": 21289267,
                    "title": "The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21289267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9182,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RO5126766 inhibited Mek signaling and increased radioiodide uptake and response in transgenic animal models of papillary thyroid carcinoma driven by BRAF V600E (PMID: 27669459).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 2011,
                "therapyName": "RO5126766",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6994,
                    "pubMedId": 27669459,
                    "title": "Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27669459"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11033,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a TP53 wild-type dedifferentiated papillary thyroid carcinoma cell line treated with APG-115 demonstrated decreased cell viability and induction of cell cycle arrest and apoptosis in culture, and tumor growth suppression and tumor regression in xenograft models (PMID: 28498808).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 5826,
                "therapyName": "APG-115",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9032,
                    "pubMedId": 28498808,
                    "title": "Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28498808"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12609,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Lenvima (lenvatinib) treatment resulted in prolonged response in a papillary thyroid carcinoma patient whose disease progressed despite 3 prior therapies including Nexavar (sorafenib), Sutent (sunitinib), and Votrient (pazopanib) (PMID: 29167691).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10478,
                    "pubMedId": 29167691,
                    "title": "Long-term efficacy and safety of fourth-line multikinase inhibitor treatment with lenvatinib in a young papillary thyroid carcinoma patient.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29167691"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13763,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BLU-667 inhibited Ret signaling and proliferation of a papillary thryoid cancer cell line harboring CCDC6-RET in culture (PMID: 29657135).",
            "molecularProfile": {
                "id": 10079,
                "profileName": "CCDC6 - RET"
            },
            "therapy": {
                "id": 5530,
                "therapyName": "BLU-667",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11266,
                    "pubMedId": 29657135,
                    "title": "Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29657135"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14144,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Selpercatinib (LOXO-292) treatment resulted in an objective response rate of 83% (5/6) in RET fusion-positive papillary thyroid cancer patients (J Clin Oncol 36, 2018 (suppl; abstr 102); NCT03157128).",
            "molecularProfile": {
                "id": 2903,
                "profileName": "RET fusion"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11479,
                    "pubMedId": null,
                    "title": "A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.",
                    "url": "https://meetinglibrary.asco.org/record/161573/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16946,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Zelboraf (vemurafenib) demonstrated safety and efficacy in metastatic papillary thyroid cancer patients carrying BRAF activating mutations (PMID: 23489023).",
            "molecularProfile": {
                "id": 696,
                "profileName": "BRAF act mut"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 579,
                    "pubMedId": 23489023,
                    "title": "Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23489023"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17589,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a papillary thyroid carcinoma patient who progressed on Lenvima (lenvatinib) was found to harbor BRAF V600E and was treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) on a clinical trial, resulting in partial response in the thyroid bed, cervical and intrathoracic lymph nodes, and pulmonary lesions, with a decrease in target lesion size of 67%, and the patient remained on treatment for 18 months before stopping due to progression (PMID: 31085763).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15690,
                    "pubMedId": 31085763,
                    "title": "KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31085763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17594,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a papillary thyroid carcinoma patient with BRAF V600E who progressed on the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) was found to have an acquired KRAS G12V mutation, and was subsequently treated with Cometriq (Cabometyx, cabozantinib), resulting in a partial response with target lesion reduction of 45% (PMID: 31085763).",
            "molecularProfile": {
                "id": 32690,
                "profileName": "BRAF V600E KRAS G12V"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15690,
                    "pubMedId": 31085763,
                    "title": "KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31085763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17595,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a papillary thyroid carcinoma patient with BRAF V600E who progressed on the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) was found to have an acquired KRAS G12V mutation (PMID: 31085763).",
            "molecularProfile": {
                "id": 32690,
                "profileName": "BRAF V600E KRAS G12V"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15690,
                    "pubMedId": 31085763,
                    "title": "KRAS G12V Mutation in Acquired Resistance to Combined BRAF and MEK Inhibition in Papillary Thyroid Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31085763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18764,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vitrakvi (larotrectinib) is included in guidelines for patients with papillary thyroid carcinoma harboring an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2904,
                "profileName": "NTRK1 fusion"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18765,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Rozlytrek (entrectinib) is included in guidelines for patients with papillary thyroid carcinoma harboring an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2904,
                "profileName": "NTRK1 fusion"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18766,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Rozlytrek (entrectinib) is included in guidelines for patients with papillary thyroid carcinoma harboring an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2908,
                "profileName": "NTRK2 fusion"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18767,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Rozlytrek (entrectinib) is included in guidelines for patients with papillary thyroid carcinoma harboring an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2909,
                "profileName": "NTRK3 fusion"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18783,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vitrakvi (larotrectinib) is included in guidelines for patients with papillary thyroid carcinoma harboring an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2908,
                "profileName": "NTRK2 fusion"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18784,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Vitrakvi (larotrectinib) is included in guidelines for patients with papillary thyroid carcinoma harboring an NTRK fusion (NCCN.org).",
            "molecularProfile": {
                "id": 2909,
                "profileName": "NTRK3 fusion"
            },
            "therapy": {
                "id": 2650,
                "therapyName": "Larotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01534897",
            "title": "Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01709292",
            "title": "Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01723202",
            "title": "Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02145143",
            "title": "Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02211222",
            "title": "An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer",
            "phase": "Phase I",
            "recruitment": "Approved for marketing",
            "therapies": [
                {
                    "id": 792,
                    "therapyName": "Lenvatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02702388",
            "title": "Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 792,
                    "therapyName": "Lenvatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02973997",
            "title": "Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4782,
                    "therapyName": "Lenvatinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03002623",
            "title": "CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 709,
                    "therapyName": "CUDC-907",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03215095",
            "title": "RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1356,
                    "therapyName": "Durvalumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03319628",
            "title": "First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4094,
                    "therapyName": "XMT-1536",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03469011",
            "title": "A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 770,
                    "therapyName": "Imatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03914300",
            "title": "Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2068,
                    "therapyName": "Cabozantinib + Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04321954",
            "title": "Lenvatinib in Locally Advanced Invasive Thyroid Cancer",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 792,
                    "therapyName": "Lenvatinib",
                    "synonyms": null
                }
            ]
        }
    ]
}